nach oben

Targeted Oncology

Erschienen in:

22.11.2020 | Original Research Article

Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis

verfasst von: Xiaoyang Li, Yu Zheng, Fei Yue

Erschienen in: Targeted Oncology | Ausgabe 1/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

The prognostic value of soluble programmed cell death ligand-1 (sPD-L1) in patients with cancer has been inconsistent across previous studies.

Objective

This meta-analysis aimed to investigate the prognostic significance of sPD-L1 in human tumors.

Methods

A comprehensive search of PubMed, Web of Science, Embase, and Cochrane databases from inception to January 6, 2020 was conducted. Studies of sPD-L1 measured by enzyme-linked immunosorbent assay (ELISA) that had available hazard ratios (HRs) for survival outcomes based on high or low sPD-L1 levels were included. The primary endpoint was long-term survival, namely, overall survival (OS), and the second endpoint was short-term survival, including progression-free survival (PFS), disease-free survival (DFS), recurrence-free survival (RFS), and cancer-specific survival (CSS).

Results

A total of 21 studies, with 2413 patients, were included in this meta-analysis. Elevated sPD-L1 was associated with worse OS [HR = 2.46, 95% confidence interval (CI) 1.74–3.49, P < 0.001]. Moreover, high sPD-L1 was predictive of worse PFS/DFS/RFS/CSS (HR = 2.22, 95% CI 1.47–3.35, P < 0.001). High sPD-L1 was consistently correlated with poor OS and PFS/DFS/RFS/CSS irrespective of study design, sample, and cut-off value of sPD-L1. However, there was non-significant correlation between sPD-L1 and sex, age, clinical stage, Eastern Cooperative Oncology Group Performance Status, tumor differentiation, or serum lactate dehydrogenase.

Conclusions

This meta-analysis showed that sPD-L1 was correlated with poor prognosis in human tumors. In addition, sPD-L1 could be used as a predictive factor of inferior outcomes during multiple malignancy treatments.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.CrossRefPubMed

Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5(12):1749–68. https://doi.org/10.1001/jamaoncol.2019.2996.CrossRefPubMedPubMedCentral

Constantinidou A, Alifieris C, Trafalis DT. Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy. Pharmacol Ther. 2019;194:84–106. https://doi.org/10.1016/j.pharmthera.2018.09.008.CrossRefPubMed

Dermani FK, Samadi P, Rahmani G, Kohlan AK, Najafi R. PD-1/PD-L1 immune checkpoint: Potential target for cancer therapy. J Cell Physiol. 2019;234(2):1313–25. https://doi.org/10.1002/jcp.27172.CrossRefPubMed

Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol Immunother. 2017;66(5):551–64. https://doi.org/10.1007/s00262-017-1954-6.CrossRefPubMed

Wu P, Wu D, Li LJ, Chai Y, Huang J. PD-L1 and survival in solid tumors: a meta-analysis. PLoS ONE. 2015;10(6):e0131403. https://doi.org/10.1371/journal.pone.0131403.CrossRefPubMedPubMedCentral

Pyo JS, Kang G, Kim JY. Prognostic role of PD-L1 in malignant solid tumors: a meta-analysis. Int J Biol Markers. 2017;32(1):E68–74. https://doi.org/10.5301/jbm.5000225.CrossRefPubMed

Tang C, Chang JY. PD-L1 expression in lung cancer. J Thorac Dis. 2016;8(11):3053–5. https://doi.org/10.21037/jtd.2016.11.38.CrossRefPubMedPubMedCentral

Huang SY, Lin HH, Lin CW, Li CC, Yao M, Tang JL, et al. Soluble PD-L1: a biomarker to predict progression of autologous transplantation in patients with multiple myeloma. Oncotarget. 2016;7(38):62490–502. https://doi.org/10.18632/oncotarget.11519.CrossRefPubMedPubMedCentral

10.

Vecchiarelli S, D’Incecco A, Gallo M, De Luca A, Minuti G, Landi L, et al. Circulating programmed death ligand-1 (PD-L1) in non-small cell lung cancer (NSCLC). Ann Oncol. 2017;28(Suppl 6):vi62. https://doi.org/10.1093/annonc/mdx426.027.CrossRef

11.

Gong B, Kiyotani K, Sakata S, Nagano S, Kumehara S, Baba S, et al. Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer. J Exp Med. 2019;216(4):982–1000. https://doi.org/10.1084/jem.20180870.CrossRefPubMedPubMedCentral

12.

Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014;28(12):2367–75. https://doi.org/10.1038/leu.2014.137.CrossRefPubMed

13.

Zheng Z, Bu Z, Liu X, Zhang L, Li Z, Wu A, et al. Level of circulating PD-L1 expression in patients with advanced gastric cancer and its clinical implications. Chin J Cancer Res. 2014;26(1):104–11. https://doi.org/10.3978/j.issn.1000-9604.2014.02.08.CrossRefPubMedPubMedCentral

14.

Zhang J, Gao J, Li Y, Nie J, Dai L, Hu W, et al. Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics. Thorac Cancer. 2015;6(4):534–8. https://doi.org/10.1111/1759-7714.12247.CrossRefPubMedPubMedCentral

15.

Fukuda T, Kamai T, Masuda A, Nukui A, Abe H, Arai K, et al. Higher preoperative serum levels of PD-L1 and B7–H4 are associated with invasive and metastatic potential and predictable for poor response to VEGF-targeted therapy and unfavorable prognosis of renal cell carcinoma. Cancer Med. 2016;5(8):1810–20. https://doi.org/10.1002/cam4.754.CrossRefPubMedPubMedCentral

16.

Takahashi N, Iwasa S, Sasaki Y, Shoji H, Honma Y, Takashima A, et al. Serum levels of soluble programmed cell death ligand 1 as a prognostic factor on the first-line treatment of metastatic or recurrent gastric cancer. J Cancer Res Clin Oncol. 2016;142(8):1727–38. https://doi.org/10.1007/s00432-016-2184-6.CrossRefPubMed

17.

Sideras K, de Man RA, Harrington SM, Polak WG, Zhou G, Schutz HM, et al. Circulating levels of PD-L1 and galectin-9 are associated with patient survival in surgically treated hepatocellular carcinoma independent of their intra-tumoral expression levels. Sci Rep. 2019;9(1):10677. https://doi.org/10.1038/s41598-019-47235-z.CrossRefPubMedPubMedCentral

18.

Wei W, Xu B, Wang Y, Wu C, Jiang J, Wu C. Prognostic significance of circulating soluble programmed death ligand-1 in patients with solid tumors: a meta-analysis. Medicine (Baltimore). 2018;97(3):e9617. https://doi.org/10.1097/md.0000000000009617.CrossRefPubMedPubMedCentral

19.

Ding Y, Sun C, Li J, Hu L, Li M, Liu J, et al. The prognostic significance of soluble programmed death ligand 1 expression in cancers: a systematic review and meta-analysis. Scand J Immunol. 2017;86(5):361–7. https://doi.org/10.1111/sji.12596.CrossRefPubMed

20.

Moher D, Liberati A, Tetzlaff J, Altman DG, Grp P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol. 2009;62(10):1006–12. https://doi.org/10.1016/j.jclinepi.2009.06.005.CrossRefPubMed

21.

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007;8:16. https://doi.org/10.1186/1745-6215-8-16.CrossRefPubMedPubMedCentral

22.

Stang A. Critical evaluation of the Newcastle–Ottawa Scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5. https://doi.org/10.1007/s10654-010-9491-z.CrossRefPubMed

23.

Cochran W. The combination of estimates from different experiments. Biometrics. 1954;10:101–29.CrossRef

24.

Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. https://doi.org/10.1002/sim.1186.CrossRefPubMed

25.

Wang H, Wang L, Liu WJ, Xia ZJ, Huang HQ, Jiang WQ, et al. High post-treatment serum levels of soluble programmed cell death ligand 1 predict early relapse and poor prognosis in extranodal NK/T cell lymphoma patients. Oncotarget. 2016;7(22):33035–45. https://doi.org/10.18632/oncotarget.8847.CrossRefPubMedPubMedCentral

26.

Okuma Y, Hosomi Y, Nakahara Y, Watanabe K, Sagawa Y, Homma S. High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancer. Lung Cancer. 2017;104:1–6. https://doi.org/10.1016/j.lungcan.2016.11.023.CrossRefPubMed

27.

Zhao J, Zhang P, Wang JH, Xi QS, Zhao XQ, Ji MH, et al. Plasma levels of soluble programmed death ligand-1 may be associated with overall survival in nonsmall cell lung cancer patients receiving thoracic radiotherapy. Medicine. 2017;96(7):e6102. https://doi.org/10.1097/md.0000000000006102.CrossRefPubMedPubMedCentral

28.

Akutsu Y, Murakami K, Kano M, Toyozumi T, Matsumoto Y, Takahashi M, et al. The concentration of programmed cell death-ligand 1 in the peripheral blood is a useful biomarker for esophageal squamous cell carcinoma. Esophagus. 2018;15(2):103–8. https://doi.org/10.1007/s10388-018-0604-1.CrossRefPubMed

29.

Jin J, Si J, Liu Y, Wang H, Ni R, Wang J. Elevated serum soluble programmed cell death ligand 1 concentration as a potential marker for poor prognosis in small cell lung cancer patients with chemotherapy. Respir Res. 2018;19(1):197. https://doi.org/10.1186/s12931-018-0885-x.CrossRefPubMedPubMedCentral

30.

Kim HJ, Park S, Kim KJ, Seong J. Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy. Radiother Oncol. 2018;129(1):130–5. https://doi.org/10.1016/j.radonc.2017.11.027.CrossRefPubMed

31.

Okuma Y, Wakui H, Utsumi H, Sagawa Y, Hosomi Y, Kuwano K, et al. Soluble programmed cell death ligand 1 as a novel biomarker for nivolumab therapy for non-small-cell lung cancer. Clin Lung Cancer. 2018;19(5):410. https://doi.org/10.1016/j.cllc.2018.04.014.CrossRefPubMed

32.

Aghajani MJ, Roberts TL, Yang T, McCafferty CE, Caixeiro NJ, DeSouza P, et al. Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer. Endocr Connect. 2019;8(7):1040–51. https://doi.org/10.1530/ec-19-0210.CrossRefPubMedPubMedCentral

33.

Bian B, Fanale D, Dusetti N, Roque J, Pastor S, Chretien AS, et al. Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma. Oncoimmunology. 2019;8(4):e1561120. https://doi.org/10.1080/2162402x.2018.1561120.CrossRefPubMedPubMedCentral

34.

Han X, Gu YK, Li SL, Chen H, Chen MS, Cai QQ, et al. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma. J Cancer Res Clin Oncol. 2019;145(2):303–12. https://doi.org/10.1007/s00432-018-2758-6.CrossRefPubMed

35.

Ito M, Yajima S, Suzuki T, Oshima Y, Nanami T, Sumazaki M, et al. High serum PD-L1 level is a poor prognostic biomarker in surgically treated esophageal cancer. Cancer Med. 2020;9(4):1321–7. https://doi.org/10.1002/cam4.2789.CrossRefPubMed

36.

Shen HR, Ji YL, Zhou DB, Zhang Y, Wang W, Sun J, et al. Soluble programmed death-ligand 1 are highly expressed in peripheral T-cell lymphoma: a biomarker for prognosis. Hematology. 2019;24(1):392–8. https://doi.org/10.1080/16078454.2019.1590965.CrossRefPubMed

37.

Shigemori T, Toiyama Y, Okugawa Y, Yamamoto A, Yin C, Narumi A, et al. Soluble PD-L1 expression in circulation as a predictive marker for recurrence and prognosis in gastric cancer: direct comparison of the clinical burden between tissue and serum PD-L1 expression. Ann Surg Oncol. 2019;26(3):876–83. https://doi.org/10.1245/s10434-018-07112-x.CrossRefPubMed

38.

Tominaga T, Akiyoshi T, Yamamoto N, Taguchi S, Mori S, Nagasaki T, et al. Clinical significance of soluble programmed cell death-1 and soluble programmed cell death-ligand 1 in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. PLoS ONE. 2019;14(2):e0212978. https://doi.org/10.1371/journal.pone.0212978.CrossRefPubMedPubMedCentral

39.

Ugurel S, Schadendorf D, Horny K, Sucker A, Schramm S, Utikal J, et al. Elevated baseline serum PD-1 or PD-L1 predicts poor outcome of PD-1 inhibition therapy in metastatic melanoma. Ann Oncol. 2020;31(1):144–52. https://doi.org/10.1016/j.annonc.2019.09.005.CrossRefPubMed

40.

Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434–52. https://doi.org/10.1016/j.immuni.2018.03.014.CrossRefPubMedPubMedCentral

41.

Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI Insight. 2019;4(6):e126908. https://doi.org/10.1172/jci.insight.126908.CrossRefPubMedCentral

42.

Wang YT, Wang HB, Yao H, Li CS, Fang JY, Xu J. Regulation of PD-L1: emerging routes for targeting tumor immune evasion. Front Pharmacol. 2018;9:536. https://doi.org/10.3389/fphar.2018.00536.CrossRefPubMedPubMedCentral

43.

Chen G, Huang AC, Zhang W, Zhang G, Wu M, Xu W, et al. Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response. Nature. 2018;560(7718):382. https://doi.org/10.1038/s41586-018-0392-8.CrossRefPubMedPubMedCentral

44.

Poggio M, Hu TY, Pai CC, Chu B, Belair CD, Chang A, et al. Suppression of exosomal PD-L1 induces systemic anti-tumor immunity and memory. Cell. 2019;177(2):414. https://doi.org/10.1016/j.cell.2019.02.016.CrossRefPubMedPubMedCentral

45.

Sanmamed MF, Chen LP. Inducible expression of B7–H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J. 2014;20(4):256–61. https://doi.org/10.1097/ppo.0000000000000061.CrossRefPubMedPubMedCentral

46.

Gani F, Nagarajan N, Kim Y, Zhu QF, Luan L, Bhaijjee F, et al. Program death 1 immune checkpoint and tumor microenvironment: implications for patients with intrahepatic cholangiocarcinoma. Ann Surg Oncol. 2016;23(8):2610–7. https://doi.org/10.1245/s10434-016-5101-y.CrossRefPubMed

47.

Zou WP, Chen LP. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008;8(6):467–77. https://doi.org/10.1038/nri2326.CrossRefPubMed

48.

Weber M, Wehrhan F, Baran C, Agaimy A, Buttner-Herold M, Preidl R, et al. PD-L1 expression in tumor tissue and peripheral blood of patients with oral squamous cell carcinoma. Oncotarget. 2017;8(68):112584–97. https://doi.org/10.18632/oncotarget.22576.CrossRefPubMedPubMedCentral

49.

Arantes L, De Carvalho AC, Melendez ME, Carvalho AL. Serum, plasma and saliva biomarkers for head and neck cancer. Expert Rev Mol Diagn. 2018;18(1):85–112. https://doi.org/10.1080/14737159.2017.1404906.CrossRefPubMed

Titel: Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis
verfasst von: Xiaoyang Li
Yu Zheng
Fei Yue
Publikationsdatum: 22.11.2020
Verlag: Springer International Publishing
Erschienen in: Targeted Oncology / Ausgabe 1/2021
Print ISSN: 1776-2596
Elektronische ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-020-00763-5

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Prognostic Value of Soluble Programmed Cell Death Ligand-1 (sPD-L1) in Various Cancers: A Meta-analysis

Abstract

Background

Objective

Methods

Results

Conclusions

Neu im Fachgebiet Onkologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Onkologie

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2021

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors

Phase I Study of Rucaparib in Combination with Bevacizumab in Ovarian Cancer Patients: Maximum Tolerated Dose and Pharmacokinetic Profile

Real-World Healthcare Resource Utilization in Patients with Classical Hodgkin Lymphoma Treated with Pembrolizumab and Nivolumab in the USA

Correction to: SB8: A Bevacizumab Biosimilar

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial

Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers

Neu im Fachgebiet Onkologie

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Erhöhte Mortalität bei postpartalem Brustkrebs

Update Onkologie